CombiMatrix Corporation (NASDAQ:CBMX), founded in 1995 and currently headquartered in Irvine, CA, is involved in the field of molecular diagnostics with a primary focus on prenatal and postnatal genetic testing, miscarriage/stillbirth management and the diagnosis of developmental disorders (and to a lesser extent hematology/oncology genetic testing). The company performs a variety of methods of genetic testing out of its CLIA and CAP-certified lab including chromosomal microarray analysis (CMA).
While the company also offers other types of genetic tests for areas outside of prenatal disorders, including fluorescence in situ hybridization (FISH) for genetic abnormalities associated with cancer and hematological diseases, and traditional karyotyping, CBMX has recently shifted the majority of its focus for growth on CMA in the
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|